Indians claim malaria cure |
Three Bengaluru scientists led a team of global researchers that are ready to go to clinical trials on humans for a potential malaria cure. The drug has the potential to cure the dreaded disease in one dose. The solution of Triaminopyrimidine (TAP) comes with many advantages over existing drugs. It is a fast-killing and long-acting anti-malarial clinical candidate. TAP acts exclusively on the blood stage of Plasmodium Falciparum (the stage responsible for clinical symptoms) in a relevant mouse model. This candidate is equally active against causative agent Plasmodium vivax. The compound has shown good safety margins in guinea pigs and rats. With a predicted half-life of 36 hours in humans, TAP offers potential for a single dose combination.
|
|
|
|